A corporate VC firm based in Asia is focused on aggregating technologies in women’s health. The firm invests from an evergreen fund and is a multi-stage investor. Typical investments range from USD 1-5 million, but the fund may make larger tranched investments in the case of therapeutic opportunities. The firm invests in companies worldwide and can act as either a lead investor or co-investor.
The firm is currently focused on building a cluster of technologies in women’s health, across the therapeutic, medical device, diagnostic and healthcare IT sectors. The firm is particularly interested in reproductive health, triple-negative breast cancer, and ovarian cancer, but will consider any opportunity in women’s health. The firm will invest in technologies at any stage of development, including very early-stage technologies. In the medtech space, the firm has a preference for 510k pathways but will look at PMA opportunities if the technology is sufficiently interesting.
The firm may or may not take a board seat in a portfolio company. If a company is seeking to expand into Asia, the firm can leverage the capabilities of its parent company to help companies with global distribution and scale up.
If you are interested in more information about this investor and other investors tracked by LSN, please email firstname.lastname@example.org